|
|
|
Volumn 53, Issue 4, 1998, Pages 220-222
|
|
Alendronate (Fosamax®);PHARMA-CLINICS. LE MEDICAMENT DU MOIS. L'ALENDRONATE (FOSAMAX(TM))
a
|
|
Author keywords
Bone densitometry; Estrogen; Fractures; Osteoporosis; Post menopause; Prevention
|
|
Indexed keywords
ALENDRONIC ACID;
ABDOMINAL PAIN;
BONE MINERALIZATION;
BONE TURNOVER;
CONSTIPATION;
DENSITOMETRY;
DIARRHEA;
DIET;
DRUG BIOAVAILABILITY;
DYSPEPSIA;
DYSPHAGIA;
ESOPHAGUS ULCER;
EXERCISE;
FEMALE;
FLATULENCE;
FRACTURE;
HUMAN;
METEORISM;
ORAL DRUG ADMINISTRATION;
OSTEOPOROSIS;
POSTMENOPAUSE;
SHORT SURVEY;
ABSORPTION;
ARTICLE;
BIOAVAILABILITY;
BONE;
BONE DENSITY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DIET RESTRICTION;
DRUG EFFECT;
OSTEOCLAST;
POSTMENOPAUSE OSTEOPOROSIS;
RANDOMIZED CONTROLLED TRIAL;
SPINE FRACTURE;
ABSORPTION;
ALENDRONATE;
BIOLOGICAL AVAILABILITY;
BONE AND BONES;
BONE DENSITY;
FASTING;
FEMALE;
FRACTURES, BONE;
HUMANS;
OSTEOCLASTS;
OSTEOPOROSIS, POSTMENOPAUSAL;
RANDOMIZED CONTROLLED TRIALS;
SPINAL FRACTURES;
|
|
EID: 0032038923
PISSN: 00353663
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
|
Times cited : (11)
|
|
References (10)
|
